Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.55 |
| ▸ | BUB1 | O43683 | 1/20 | 0.54 |
| ▸ | PRKACG | P22612 | 1/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.54 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409067 | 0.78 | MAPK14 (0.82) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL2216235 | 0.76 | MAPK14 (0.43) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL2215180 | 0.76 | MAPK14 (0.52) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3410765 | 0.75 | MAPK14 (0.78) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3408716 | 0.75 | MAPK14 (0.78) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3405520 | 0.75 | MAPK14 (0.74) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448647 | 0.74 | MAPK14 (0.76) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3409256 | 0.74 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL2215030 | 0.73 | MAPK14 (0.42) | MAPK14CYP2C9 | |
| SCHEMBL20448609 | 0.72 | MAPK14 (0.57) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 14/4885CYP2C9 2372/4885MAPK11 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.